Team:Exeter/Achievements

From 2012.igem.org

(Difference between revisions)
(Created page with "{{Template:Team:Exeter/e-candi_banner}} 475px")
Line 1: Line 1:
{{Template:Team:Exeter/e-candi_banner}}
{{Template:Team:Exeter/e-candi_banner}}
-
[[Image: Exe12_page_udrconstruct.png|center|475px]]
+
<html xmlns="http://www.w3.org/1999/xhtml">
 +
<head>
 +
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
 +
<title>Protocol 6</title>
 +
 
 +
</head>
 +
 
 +
<body>
 +
<table width="980" align="center" cellspacing="10">
 +
 
 +
  <!--Spacer for Menu Banner-->
 +
    <tr>
 +
    <td height="20"></td>
 +
    </tr>
 +
  <!--End of Spacer-->
 +
 
 +
<tr align="justify">
 +
  <td>
 +
  <font color="#57B947" size="+2" face="Verdana">Achievements and Failures</font>
 +
  </td>
 +
</tr>
 +
 
 +
 +
<tr align="justify">
 +
  <td>
 +
  <font color="#1b1b1d" size="2" face="Verdana">
 +
    <p><b>Achievements</b></p>
 +
    <ul>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Successfully cloned and submitted 32 biobricks into the registry</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Obtained WbbC gene from BL21 genome</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Created GlycoBase; a database containing a list of >100 glycosyltransferase enzymes
 +
    from <i>E.coli</i> strains to demonstrate the vast linkages we could achieve only with <i>E.coli</i> enzymes</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Created GlycoWeb, an interface for an online user to access Glycobase with a
 +
    polysaccharide in mind and the database searches and finds the enzymes you’d use to make it.</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Created GlycoApp; an application for a handheld device to access the Glycobase from
 +
    wherever the consumer is when they realise they need a polysaccharide ordering!</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Considered human practice approaches and discussed with several experts the human
 +
    practice considerations, hosted a human practice panel and discussed with the wider community at Café Scientifique.</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Discussed our project with various businesses including Shell, Ginsters etc. and we
 +
    received letters of support from DSTL, ISCA Biochemical Ltd, Avon. </li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Demonstrated that….. Successfully expressed this polysaccharide….. (to be cont….)</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/9/99/Exe2012Tick.jpg);">Made promoter-RBS-gene-terminator constructs for each gene</li>
 +
    </ul>
 +
   
 +
    <p><b>Failures</b></p>
 +
    <ul>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/1/11/Exe2012Cross.png);">A correct mass analysis of the product is essential, but cannot alone confirm the
 +
    correct product. The possibility that an incorrect product has been made through incorrect synthesis or post-synthetic regiospecific or enantiospecific rearrangement by
 +
    chemical or enzymatic means must be examined and ruled out before the method can be considered reliable.</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/1/11/Exe2012Cross.png);">Synthesis of a previously well characterised small polysaccharide, which can be
 +
    physically and also biochemically characterised, to show that the product will act in biological systems as expected. Once a fully characterised polysaccharide is produced, we
 +
    would be in a much stronger position to offer novel products and to start to address the exciting possibilities of our method.</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/1/11/Exe2012Cross.png);">Only managed to obtain 7 of 9 fragments for Gibson assembly through PCR.</li>
 +
    <li style="list-style-image: url(https://static.igem.org/mediawiki/2012/1/11/Exe2012Cross.png);">Didn’t manage to construct operons through BioBrick assembly.</li>
 +
    </ul>
 +
  </font>
 +
  </td>
 +
</tr>
 +
 
 +
</table>
 +
 
 +
</body>
 +
</html>

Revision as of 01:43, 25 September 2012

Protocol 6

Achievements and Failures

Achievements

  • Successfully cloned and submitted 32 biobricks into the registry
  • Obtained WbbC gene from BL21 genome
  • Created GlycoBase; a database containing a list of >100 glycosyltransferase enzymes from E.coli strains to demonstrate the vast linkages we could achieve only with E.coli enzymes
  • Created GlycoWeb, an interface for an online user to access Glycobase with a polysaccharide in mind and the database searches and finds the enzymes you’d use to make it.
  • Created GlycoApp; an application for a handheld device to access the Glycobase from wherever the consumer is when they realise they need a polysaccharide ordering!
  • Considered human practice approaches and discussed with several experts the human practice considerations, hosted a human practice panel and discussed with the wider community at Café Scientifique.
  • Discussed our project with various businesses including Shell, Ginsters etc. and we received letters of support from DSTL, ISCA Biochemical Ltd, Avon.
  • Demonstrated that….. Successfully expressed this polysaccharide….. (to be cont….)
  • Made promoter-RBS-gene-terminator constructs for each gene

Failures

  • A correct mass analysis of the product is essential, but cannot alone confirm the correct product. The possibility that an incorrect product has been made through incorrect synthesis or post-synthetic regiospecific or enantiospecific rearrangement by chemical or enzymatic means must be examined and ruled out before the method can be considered reliable.
  • Synthesis of a previously well characterised small polysaccharide, which can be physically and also biochemically characterised, to show that the product will act in biological systems as expected. Once a fully characterised polysaccharide is produced, we would be in a much stronger position to offer novel products and to start to address the exciting possibilities of our method.
  • Only managed to obtain 7 of 9 fragments for Gibson assembly through PCR.
  • Didn’t manage to construct operons through BioBrick assembly.